Cerenome, Inc. CNSY
0.62 USD -0.10 (-13.77%)
As ofNov 17, 2026, 12:18 PM EST
0.6006 Day range 0.7083
0.43 52-week range 19.00
- YTD
- -95.17%
- 1 year
- -94.86%
- Market cap
- 5.96M
- EPS (ttm)
- -3.36
- YTD return
- -95.17%
- 1-year return
- -94.86%
- Volume
- 171.63K
- Avg volume
- 788.27K
- Open
- 0.7083
- Previous close
- 0.7148
- Day's range
- 0.6006 – 0.7083
- 52-week range
- 0.43 – 19.00
5D +0.1744 (+32.27%)
Fundamental scorecard
8 of 25 checks passed on CNSY’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
CNSY Revenue — quarterly 411.00K
CNSY Net income — quarterly -9.01M
CNSY EPS — quarterly -1.31
News
Cerenome, Inc. (CNSY) Q3 2026 Earnings Call Transcript Cerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates Cerenome Q3 EPS $(1.14) Misses $(0.95) Estimate, Sales $722.000K Miss $920.333K Estimate
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
12 Health Care Stocks Moving In Friday's Intraday Session
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
Cerenome Appoints Director Ron Andrews as Chief Business Officer
12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on CNSY — it syncs with the Stock Master app.
